The Molecular Imaging Biomarker-Based End of Therapy Trial (MI-BET) is a novel theranostics study, designed to explore a personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer.
“This collaboration is an example of how Mayo Clinic leads in discovery by integrating novel technologies into our practice and accelerating innovation across research and clinical care to advance the future of medicine,” said Mayo Clinic Chief Business Development Officer Andrew Danielsen in a news release.
“By bringing together complementary expertise and capabilities, we can enable our world-class researchers and physicians to develop new insights, expand treatment possibilities, and ultimately provide the best outcomes for our patients globally,” he continued.
Related: Siemens Healthineers, Mayo Clinic collab to treat neurodegenerative disease
Radioligand therapy is an emerging treatment within theranostics, combining targeted radiopharmaceutical diagnostics and therapies that allow clinicians to identify and treat cancer with greater precision, the news release said.
Right now, patients undergoing RTL follow a standardized, preset number of treatment cycles, according to the release. MI-BET is designed to evaluate whether imaging and biomarker-informed insights can support a more personalized approach to cancer treatment.
“Making theranostics truly adaptive and personalized requires strong clinical evidence and a deeper understanding of how patients respond to therapy,” said GE HealthCare Global Theranostics GM Sergio Calvo. “Through our collaboration with Mayo Clinic, we are exploring how imaging and data-driven insights can help inform more individualized treatment decisions, support the broader adoption of these approaches and contribute to the continued growth of precision care in oncology.”
Insights from the study could also potentially support the development of predictive markers for patients’ response to treatment. Predictive marker insights could allow researchers and clinicians to anticipate how a patient will respond before or early in treatment, enabling care teams to make adaptive treatment decisions, the release said.
“Personalizing therapy is both a scientific pursuit and an opportunity to expand patient access,” Chair of the Radiopharmaceutical Trial Team at Mayo Clinic, Dr. Geoffrey Johnson said. “Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer. By evaluating response earlier in their treatment, we can generate data to drive approaches that could help reduce unnecessary therapy while expanding access to care for wider populations.”
Related: GE HealthCare earns FDA nod for AI-enabled radiotherapy tech
The collaboration and trial support a broader goal of expanding access to advanced, the release said. The study design encourages broad participation through patient outreach, collaboration with community and advocacy groups and uses approaches, like telemedicine, that could help reduce barriers to enrollment and engagement.
MI-BET research and related activities will be based at Mayo Clinic’s campus in Rochester, Minnesota. Mayo Clinic will also be the first U.S. site to investigate the potential benefits of GE HealthCare’s next-generation SPECT/CT StarGuide GX technology, including exploring the potential for reducing scan time and increasing the precision of tumor assessment. StarGuide GX is currently not cleared by the FDA but has received the CE mark.
